Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 4 | 9 |
| 1.1 List of Tables | 7 | 3 |
| 1.2 List of Figures | 10 | 3 |
| 2 Global Pain Management Therapeutics Market: Introduction | 13 | 1 |
| 2.1 GBI Research Report Guidance | 13 | 1 |
| 3 Global Pain Management Therapeutics Market: Market Overview | 14 | 12 |
| 3.1 Introduction | 14 | 1 |
| 3.2 Revenue Forecast for the Global Pain Management Therapeutics Market | 15 | 1 |
| 3.2.1 Sales Value | 15 | 1 |
| 3.2.2 Patient Volume | 16 | 1 |
| 3.2.3 Annual Cost of Therapy | 17 | 1 |
| Treatment Usage Patterns | 18 | 1 |
| 3.2.4.1 Diseased Population | 19 | 1 |
| 3.2.4.2 Treatment Seeking Population | 20 | 1 |
| 3.2.4.3 Diagnosed Population | 21 | 1 |
| 3.2.4.4 Prescription Population | 22 | 1 |
| 3.2.5 Generics Share in the Global Pain Management Therapeutics Market | 23 | 1 |
| 3.2.6 Sales of Leading Drugs | 24 | 1 |
| 3.3 Pain Management Therapeutics Market Drivers | 25 | 1 |
| 3.3.1 Increase in Diagnosed and Prescription Population | 25 | 1 |
| Global Pain Management Therapeutics Market: Therapeutic Landscape | 26 | 49 |
| 4.1 Fibromyalgia Market | 26 | 1 |
| 4.1.1 Introduction | 26 | 1 |
| 4.1.2 Sales Value | 26 | 2 |
| 4.1.3 Patient Volume | 28 | 1 |
| 4.1.4 Annual Cost of Therapy | 29 | 1 |
| 4.1.5 Treatment Usage Patterns | 30 | 2 |
| 4.1.5.1 Diseased Population | 32 | 1 |
| 4.1.5.2 Treatment Seeking Population | 33 | 1 |
| 4.1.5.3 Diagnosed Population | 34 | 1 |
| 4.1.5.4 Prescription Population | 35 | 1 |
| Drivers for Fibromyalgia Pain Market | 35 | 1 |
| 4.1.6.1 Ageing Population Will Drive Prevalence | 35 | 1 |
| 4.1.6.2 Improvement in Awareness and Resultant Diagnosis Levels Will Drive the Market | 36 | 1 |
| 4.1.6.3 Substantial Unmet Need increases the Market Potential | 36 | 1 |
| 4.1.7 Restraints for Fibromyalgia Pain Market | 36 | 1 |
| 4.1.7.1 Limitations in the Efficacy of Existing Drugs Leads Can Potentially Lead to Low Prescription | 36 | 1 |
| 4.1.7.2 Inadequate Knowledge of Disease Progression Hinder the Development of Drugs With Better Efficacy | 36 | 1 |
| 4.1.8 Unmet Needs | 36 | 1 |
| 4.2 Neuropathic Pain Market | 36 | 1 |
| 4.2.1 Introduction | 36 | 1 |
| 4.2.2 Sales Value | 37 | 1 |
| 4.2.3 Patient Volume | 38 | 1 |
| 4.2.4 Annual Cost of Therapy | 39 | 1 |
| 4.2.5 Treatment Usage Patterns | 40 | 2 |
| 4.2.5.1 Diseased Population | 42 | 1 |
| 4.2.5.2 Treatment Seeking Population | 43 | 1 |
| 4.2.5.3 Diagnosed Population | 44 | 1 |
| 4.2.5.4 Prescription Population | 45 | 1 |
| 4.2.6 Drivers for Neuropathic Pain Market | 45 | 1 |
| 4.2.6.1 Ageing Population and Increasing Prevalence of Diabetes and HIV Will Drive The Prevalence of Neuropathic Pain Which is Known to Be High in Aged Population | 45 | 1 |
| 4.2.6.2 A more Active Treatment Seeking Behavior to Drive Increase in Patient Volume | 45 | 1 |
| 4.2.7 Restraints for Neuropathic Pain Market | 46 | 1 |
| 4.2.7.1 Non Availability of Accurate Tools that Aid Diagnosis Is a Hindrance for Market Growth | 46 | 1 |
| 4.2.8 Unmet Need | 46 | 1 |
| 4.3 Migraine Market | 46 | 1 |
| 4.3.1 Introduction | 46 | 1 |
| 4.3.2 Sales Value | 47 | 1 |
| 4.3.3 Patient Volume | 48 | 1 |
| 4.3.4 Annual Cost of Therapy | 49 | 1 |
| 4.3.5 Treatment Usage Patterns | 50 | 2 |
| 4.3.5.1 Diseased Population | 52 | 1 |
| 4.3.5.2 Treatment Seeking Population | 53 | 1 |
| 4.3.5.3 Diagnosed Population | 54 | 1 |
| 4.3.5.4 Prescription Population | 55 | 1 |
| 4.3.6 Drivers for Migraine Market | 55 | 1 |
| 4.3.6.1 The Increasing Awareness Will Result In Increasing Prescription Rate | 55 | 1 |
| 4.3.7 Restraints for Migraine Market | 55 | 1 |
| 4.3.7.1 Low Treatment Seeking Behavior and Diagnosis Rate Restrain the Growth in Prescription Population | 55 | 1 |
| 4.3.7.2 Falling Prices of Migraine Treatment Will Restrain the Market by Off setting the impact of increasing volume | 56 | 1 |
| 4.3.8 Unmet Need | 56 | 1 |
| 4.4 Cancer Pain Market | 56 | 1 |
| 4.4.1 Introduction | 56 | 1 |
| 4.4.2 Sales Value | 56 | 2 |
| 4.4.3 Patient Volume | 58 | 1 |
| 4.4.4 Annual Cost of Therapy | 59 | 1 |
| 4.4.5 Treatment Usage Patterns | 60 | 1 |
| 4.4.5.1 Diseased Population | 61 | 1 |
| 4.4.5.2 Treatment Seeking Population | 62 | 1 |
| 4.4.5.3 Diagnosed Population | 63 | 1 |
| 4.4.5.4 Prescription Population | 64 | 1 |
| 4.4.6 Drivers for Cancer Pain Market | 64 | 1 |
| 4.4.6.1 Increasing Treatment Seeking, Diagnosis and Prescription Rate Will Drive the Market | 64 | 1 |
| 4.4.6.2 New Modes of Delivery Will Help in Better Management of the Pain for a Longer Duration | 65 | 1 |
| 4.4.7 Restraints for Cancer Pain Market | 65 | 1 |
| 4.4.7.1 Concerns Over the Risks of Addiction Related to Drug Therapy Will Affect the Prescription Rate | 65 | 1 |
| 4.4.8 Unmet Need | 65 | 1 |
| 4.5 Osteoarthritis Pain Market | 65 | 1 |
| 4.5.1 Introduction | 65 | 1 |
| 4.5.2 Sales Value | 66 | 1 |
| 4.5.3 Patient Volume | 67 | 1 |
| 4.5.4 Annual Cost of Therapy | 68 | 1 |
| 4.5.5 Treatment Usage Patterns | 69 | 1 |
| 4.5.5.1 Diseased Population | 70 | 1 |
| 4.5.5.2 Treatment Seeking Population | 71 | 1 |
| 4.5.5.3 Diagnosed Population | 72 | 1 |
| 4.5.5.4 Prescription Population | 73 | 1 |
| 4.5.6 Drivers for Osteoarthritis Pain Market | 73 | 1 |
| 4.5.6.1 An Aging Population | 73 | 1 |
| 4.5.6.2 Increase in the Obese Population Which is Associated with a Higher Risk of Osteoarthritis Will Drive Volume | 73 | 1 |
| 4.5.7 Restraints for Osteoarthritis Pain Market | 74 | 1 |
| 4.5.7.1 Low Treatment Seeking and Diagnosis Rate | 74 | 1 |
| 4.5.8 Unmet Need | 74 | 1 |
| 5 Global Pain Management Therapeutics Market: Geographical Landscape | 75 | 27 |
| 5.1 Geographical Break-up | 75 | 2 |
| 5.2 The US | 77 | 1 |
| 5.2.1 Sales Value | 77 | 1 |
| 5.2.2 Patient Volume | 78 | 1 |
| 5.2.3 Annual Cost of Therapy | 79 | 1 |
| 5.2.4 Treatment Usage Patterns | 80 | 1 |
| 5.2.4.1 Diseased Population | 81 | 1 |
| 5.2.4.2 Treatment Seeking Population | 82 | 1 |
| 5.2.4.3 Diagnosed Population | 83 | 1 |
| 5.2.4.4 Prescription Population | 84 | 1 |
| 5.3 Top Five Countries in Europe | 85 | 1 |
| 5.3.1 Sales Value | 85 | 1 |
| 5.3.2 Patient Volume | 86 | 1 |
| 5.3.3 Annual Cost of Therapy | 87 | 1 |
| 5.3.4 Treatment Usage Patterns | 88 | 1 |
| 5.3.4.1 Diseased Population | 89 | 1 |
| 5.3.4.2 Treatment Seeking Population | 90 | 1 |
| 5.3.4.3 Diagnosed Population | 91 | 1 |
| 5.3.4.4 Prescription Population | 92 | 1 |
| 5.4 Japan | 93 | 1 |
| 5.4.1 Sales Value | 93 | 1 |
| 5.4.2 Patient Volume | 94 | 1 |
| 5.4.3 Annual Cost of Therapy | 95 | 1 |
| 5.4.4 Treatment Usage Patterns | 96 | 2 |
| 5.4.4.1 Diseased Population | 98 | 1 |
| 5.4.4.2 Treatment Seeking Population | 99 | 1 |
| 5.4.4.3 Diagnosed Population | 100 | 1 |
| 5.4.4.4 Prescription Population | 101 | 1 |
| 6 Global Pain Management Therapeutics Market: Pipeline Analysis | 102 | 10 |
| 6.1 Introduction | 102 | 1 |
| 6.1.1 Research and Development Pipeline Fibromyalgia | 103 | 1 |
| 6.1.2 Research and Development Pipeline Neuropathic Pain | 104 | 1 |
| 6.1.3 Research and Development Pipeline Migraine | 105 | 1 |
| 6.1.4 Research and Development Pipeline Cancer Pain | 106 | 1 |
| 6.1.5 Research and Development Pipeline Osteoarthritis Pain | 106 | 1 |
| 6.2 Profiles of Key Late-Stage Drugs in the Pain Management Market | 107 | 1 |
| 6.2.1 Droxopida | 107 | 1 |
| 6.2.1.1 Introduction | 107 | 1 |
| 6.2.1.2 Clinical Trial Management | 107 | 1 |
| 6.2.2 Xyrem | 107 | 1 |
| 6.2.2.1 Introduction | 107 | 1 |
| 6.2.2.2 Clinical Trial Management | 107 | 1 |
| 6.2.3 Vimpat (lacosamide) | 107 | 1 |
| 6.2.3.1 Introduction | 107 | 1 |
| 6.2.3.2 Clinical Trial Management | 108 | 1 |
| 6.2.4 Qutenza (capsaicin 8%) | 108 | 1 |
| 6.2.4.1 Introduction | 108 | 1 |
| 6.2.4.2 Clinical Trial Management | 109 | 1 |
| 6.2.5 Botox | 109 | 1 |
| 6.2.5.1 Introduction | 109 | 1 |
| 6.2.6 Tezampanel | 110 | 1 |
| 6.2.6.1 Introduction | 110 | 1 |
| 6.2.6.2 Clinical Trial Management | 110 | 1 |
| 6.2.7 Nasalfent | 110 | 1 |
| 6.2.7.1 Introduction | 110 | 1 |
| 6.2.7.2 Clinical Trial Management | 110 | 1 |
| 6.2.8 PF-4383119 (Tanezumab) | 111 | 1 |
| 6.2.8.1 Introduction | 111 | 1 |
| 6.2.8.2 Clinical Study Details | 111 | 1 |
| 7 Global Pain Management Therapeutics Market: Competitive Landscape | 112 | 13 |
| 7.1 Market Share Analysis | 112 | 1 |
| 7.2 Competitive Profiling | 112 | 2 |
| 7.2.1 Pfizer, Inc. | 114 | 1 |
| 7.2.1.1 Product Portfolio | 114 | 1 |
| 7.2.1.2 Product Pipeline | 115 | 1 |
| 7.2.2 Eli Lilly and Company | 115 | 1 |
| 7.2.2.1 Product Portfolio | 116 | 1 |
| 7.2.2.2 Product Pipeline | 116 | 1 |
| 7.2.3 Johnson &Johnson | 117 | 1 |
| 7.2.3.1 Product Portfolio | 118 | 1 |
| 7.2.3.2 Product Pipeline | 119 | 1 |
| 7.2.4 Endo Pharmaceuticals | 119 | 1 |
| 7.2.4.1 Product portfolio | 120 | 1 |
| 7.2.4.2 Product Pipeline | 120 | 1 |
| 7.2.5 Novartis AG | 120 | 1 |
| 7.2.5.1 Product Portfolio | 121 | 1 |
| 7.2.5.2 Product Pipeline | 122 | 1 |
| 7.2.6 Merck &Co Inc | 122 | 1 |
| 7.2.6.1 Product Portfolio | 123 | 1 |
| 7.2.6.2 Product Pipeline | 123 | 1 |
| 7.2.7 Cephalon, Inc. | 123 | 1 |
| 7.2.7.1 Product Portfolio | 124 | 1 |
| 7.2.7.2 Product Pipeline | 124 | 1 |
| 8 Global Pain Management Therapeutics Market: Strategic Consolidations | 125 | 11 |
| 8.1 Overview | 125 | 2 |
| 8.1.1 Sanofi-Aventis Acquired 100% outstanding shares of Chattem, Inc in December 2009 | 127 | 1 |
| 8.1.2 Dainippon Sumitomo Pharma Acquired Sepracor, Inc. in October 2009 | 127 | 1 |
| 8.1.3 Raptor Pharmaceuticals and TorreyPines Therapeutics Merged in August 2009 | 127 | 1 |
| 8.1.4 Alexza Pharmaceuticals Acquired Symphony Allegro in June 2009 | 127 | 1 |
| 8.1.5 Anesiva and Arcion Therapeutics Merge in May 2009 | 127 | 1 |
| 8.1.6 Mylan Laboratories Acquired Matrix Laboratories Limited in March 2009 | 128 | 1 |
| 8.2 R&D Licensing Agreements | 128 | 1 |
| 8.2.1 Deals by Indication | 128 | 1 |
| 8.2.2 Deals by Phase | 129 | 1 |
| 8.2.3 Deals by Geography | 130 | 1 |
| 8.2.4 Deals by Value ($) | 131 | 1 |
| 8.2.5 Preclinical and Discovery | 131 | 1 |
| 8.2.5.1 PL37 | 131 | 1 |
| 8.2.5.2 PRS-639058 | 131 | 1 |
| 8.2.5.3 Osteoarthritis Program | 132 | 1 |
| 8.2.6 Phase I | 132 | 1 |
| 8.2.6.1 AGN-209323 | 132 | 1 |
| 8.2.6.2 SI-000413 | 132 | 1 |
| 8.2.7 Phase II | 132 | 1 |
| 8.2.7.1 AMG 108 | 133 | 1 |
| 8.2.8 Phase III | 133 | 1 |
| 8.2.8.1 Rapinyl | 133 | 1 |
| 8.2.8.2 HFT-290 (Fentanyl) | 133 | 1 |
| 8.2.8.3 Prochymal | 133 | 1 |
| 8.2.8.4 AD 923 | 133 | 1 |
| 8.2.8.5 Civanex | 134 | 1 |
| 8.2.9 Approved and Regulatory Filing | 134 | 1 |
| 8.2.9.1 Orthovisc | 134 | 1 |
| 8.2.9.2 Onsolis | 134 | 1 |
| 8.2.9.3 Glucomed | 135 | 1 |
| 8.2.9.4 Voltaren | 135 | 1 |
| 8.2.9.5 Sumavel DosePro | 135 | 1 |
| 8.2.9.6 Qutenza | 135 | 1 |
| 8.2.9.7 Rapinyl | 135 | 1 |
| 8.2.9.8 Lyrica | 135 | 1 |
| 9 Global Pain Management Therapeutics Market: Appendix | 136 | 6 |
| 9.1 Market Definitions | 136 | 1 |
| 9.2 Abbreviations | 136 | 1 |
| 9.3 Research Methodology | 137 | 4 |
| 9.3.1 Coverage | 137 | 1 |
| 9.3.2 Secondary Research | 138 | 1 |
| 9.3.3 Primary Research | 138 | 1 |
| 9.3.4 Forecasts | 138 | 1 |
| 9.3.4.1 Epidemiology-based Forecasting | 138 | 2 |
| 9.3.5 Expert Panel Validation | 140 | 1 |
| 9.4 Contact Us | 141 | 1 |
| 9.5 Disclaimer | 141 | 1 |
| 9.6 Sources | 141 | 1 |